文献速递治疗药物监测与药物基因组学药物相互作用特殊人群用药

药物代谢酶基因多态性及合并用药对南非黑人乳腺癌女性他莫昔芬代谢的影响

Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer.
PubMed 文献 · Clin Pharmacol Ther · 2023-04-28

该研究纳入229例南非黑人激素受体阳性乳腺癌女性患者,评估合并用药及CYP2D6、CYP3A5、CYP3A4、CYP2B6、CYP2C9、CYP2C19基因多态性对他莫昔芬(TAM)药代动力学的影响。结果显示CYP2D6双倍型和表型显著影响endoxifen(ENDO)浓度(P<0.001),CYP2D6*17和*29显著降低NDM向ENDO的代谢;抗逆转录病毒治疗显著影响NDM水平及TAM/NDM、NDM/ENDO代谢比,但未显著影响ENDO水平。结论提示CYP2D6多态性影响ENDO浓度,CYP2D6*17和*29导致ENDO低暴露,而TAM药物相互作用风险较低。

要点

  • CYP2D6双倍型和表型显著影响endoxifen浓度(P<0.001)。
  • CYP2D6*17和*29显著降低NDM向ENDO的代谢。
  • 抗逆转录病毒治疗影响NDM水平及代谢比,但未显著影响ENDO水平。

核心结论

  • CYP2D6基因多态性影响endoxifen浓度,CYP2D6*17和*29显著导致ENDO低暴露。
  • 本研究提示接受TAM治疗的乳腺癌患者药物相互作用风险较低。

研究设计与样本

  • 研究纳入229例南非黑人激素受体阳性乳腺癌女性患者,评估合并用药及药物代谢酶基因多态性对TAM药代动力学的影响。
  • 使用液相色谱-质谱法测定血浆TAM及其主要代谢物NDM、4-OH-tamoxifen和ENDO浓度。
  • 采用GenoPharm open array对CYP2D6、CYP3A5、CYP3A4、CYP2B6、CYP2C9和CYP2C19进行基因分型。

主要发现

  • CYP2D6双倍型和CYP2D6表型显著影响endoxifen浓度(P<0.001和P<0.001)。
  • CYP2D6*17和CYP2D6*29显著降低NDM向ENDO的代谢。
  • 抗逆转录病毒治疗显著影响NDM水平及TAM/NDM和NDM/ENDO代谢比,但未显著影响ENDO水平。

临床怎么用

  • 对于接受他莫昔芬治疗的乳腺癌患者,应考虑CYP2D6基因型(尤其*17和*29)对endoxifen暴露的影响。
  • 合并抗逆转录病毒治疗时,需关注NDM水平及代谢比变化,但ENDO水平未受显著影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical outcomes of tamoxifen (TAM) treatment show wide interindividual variability. Comedications and genetic polymorphisms of enzymes involved in TAM metabolism contributes to this variability. Drug-drug and drug-gene interactions have seldom been studied in African Black populations. We evaluated the effects of commonly co-administered medicines on TAM pharmacokinetics in a cohort of 229 South African Black female patients with hormone-receptor positive breast cancer. We also investigated the pharmacokinetic effects of genetic polymorphism in enzymes involved in TAM metabolism, including the variants CYP2D6*17 and *29, which have been mainly reported in people of African descent. TAM and its major metabolites, N-desmethyltamoxifen (NDM), 4-OH-tamoxifen, and endoxifen (ENDO), were quantified in plasma using the liquid chromatography-mass spectrometry. The GenoPharm open array was used to genotype CYP2D6, CYP3A5, CYP3A4, CYP2B6, CYP2C9, and CYP2C19. Results showed that CYP2D6 diplotype and CYP2D6 phenotype significantly affected endoxifen concentration (P < 0.001 and P < 0.001). CYP2D6*17 and CYP2D6*29 significantly reduced the metabolism of NDM to ENDO. Antiretroviral therapy had a significant effect on NDM levels and the TAM/NDM and NDM/ENDO metabolic ratios but did not result in significant effects on ENDO levels. In conclusion, CYP2D6 polymorphisms affected endoxifen concentration and the variants CYP2D6*17 and CYP2D6*29 significantly contributed to low exposure levels of ENDO. This study also suggests a low risk of drug-drug interaction in patients with breast cancer on TAM.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chiwambutsa SM, Ayeni O, Kapungu N, et al. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer. Clin Pharmacol Ther. 2023. PMID: 37042388. doi:10.1002/cpt.2904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。